Svante Secures Commercial Supply of MOF Advanced Sorbent Materials with BASF for Carbon Capture Market
Svante announced today that it has entered into an arm’s length Commercial Supply Agreement with BASF to scale up its proprietary sorbent material, Calgary Framework 20 (CALF-20), used in Svante’s carbon capture process. This metal-organic framework (MOF) sorbent can capture up to 95% of carbon dioxide (CO2) emitted from industrial sources, such as cement and blue hydrogen plants, using rapid solid adsorption and low-pressure steam.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231010178949/en/
Svante's metal-organic framework (MOF), CALF-28, used for the company's novel carbon capture filter technology, is to be manufactured by BASF at commercial scale. (Photo: Business Wire)
Svante has pioneered carbon capture and removal technology using structured adsorbent beds, known as “filters”. The company is the most advanced industry player in the use of solid sorbents for carbon capture, with the world’s first commercially available MOF nanomaterial filter manufacturing facility in Vancouver, BC. This commercial supply agreement with BASF will unlock the next phase of Svante’s growth, scaling carbon capture filter manufacturing up to multi-million-tonne capacity and implementing hundreds of large-scale carbon capture and storage (CCS) facilities by 2030.
Svante’s unique modular and environmentally responsible solid sorbent technology is designed to capture CO2 from industrial flue gas. It then concentrates it into a high purity 95% pipeline-grade) CO2 and releases it for safe storage or further industrial use. Its unique approach is tailored specifically to the challenges of separating CO2 from nitrogen in diluted flue gas, which is typically emitted in large volumes at low pressures and in dilute concentrations. Svante’s technology will play a key role in decarbonizing industrial activity in diverse fields including hydrogen, pulp and paper, cement, steel, aluminum, and chemicals.
Svante and BASF have been working collaboratively for the last two years to scale up CALF-20, which acts as a sponge for adsorbing CO2. Results of their research, published in the international peer-reviewed journal, Science, in December 2021, demonstrated CALF-20's unique resistance to oxidation and water vapor, which allows CO2 to be captured at a low cost, using Svante’s proprietary structured adsorbent filters.
Solid sorbents are a step change for carbon capture, but the challenge is to merge all of their desirable features into a robust framework material with a low manufacturing cost. CALF-20 coupled with Svante’s filter addresses this challenge and captures CO2 with high capacity and selectivity over water.
“For high-performance CO2 capture and removal, steam stripping — where direct contact steam is used to flush CO2 out of the sorbent — has been a sort of ‘holy grail’ in the field. It is seen as the most effective way to do it,” said Claude Letourneau, President & CEO of Svante. “This MOF material, combined with our proprietary structured adsorption filters, is a game-changer for the carbon capture and removal industry. We have the right technology to reduce the capital cost of CO2 capture. It is modular and adaptable. Now, we need to scale up this technology and commercialize it to create a viable carbon management industry at gigaton scale”.
Svante, in collaboration with BASF, has successfully scaled up the CALF-20 MOF sorbent from laboratory to industrial scale by using a simple low-temperature process in accordance with green chemistry principles. Scalability and low cost of solid sorbents are imperative to the wide adoption of CCS. Up until now, large-scale production of MOF materials at low cost has been a barrier for the gas separation industry.
In addition to scaling up its CALF-20 manufacturing process, Svante has developed a high-volume and low-cost roll-to-roll process for coating the sorbent onto sheets of laminate, which it calls “Sorbent on a Roll”. The laminate is then stacked into high-performance filters, which are now available for both industrial point-source capture and direct air capture.
About Svante
Headquartered in Vancouver, BC, Canada, Svante is a purpose-driven, leading carbon capture and removal solutions provider. The company makes nanoengineered filters and modular rotary contactor machines that capture and remove CO2 in an environmentally responsible way from industrial emissions and the air. Svante is on the 2023 Global Cleantech 100, the XPRIZE Foundation’s XB100 — World’s Top 100 Deep Tech Companies, and was ranked second among private companies in the Corporate Knights’ Future 50 Fastest Growing Sustainable Companies in Canada. To learn more about Svante, visit www.svanteinc.com and follow Svante on LinkedIn or Twitter @svantesolutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231010178949/en/
Contact information
Svante
Colleen Nitta
Director of Marketing & Communications
cnitta@svanteinc.com
604-970-2813
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release
Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla
Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release
Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log
TOM FORD Unveils Black Orchid Reserve Campaign Starring Tilda Swinton29.8.2025 07:35:00 EEST | Press release
The quest for exceptional rarity. Introducing Tilda Swinton for the new TOM FORD Black Orchid Reserve campaign. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828507187/en/ “It is a profound honour for me to play a part in the history of TOM FORD’s legendary Black Orchid. Transformation, the blurring of boundaries and the celebration of magical properties have always drawn me close; Black Orchid Reserve is precisely such an enchantment.” — Tilda Swinton A celebrated actor and artist, Swinton is a singular presence known for her fearless artistry and transformative performances. An Academy Award, BAFTA and Golden Lion for Lifetime Achievement winner, Swinton defies conventions with elegance, intellect and a visionary approach to cinema. Her work transcends definition, shaping the culture through work in film, art and performance. TOM FORD creative director Haider Ackermann designed the campaign as a cinematic portrait of r
Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma28.8.2025 23:15:00 EEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ Pharma) in achieving a significant regulatory milestone: the approval of Anlotinib Hydrochloride Capsules for a new indication as a first-line treatment for unresectable locally advanced or metastatic soft tissue sarcoma (STS) in combination with chemotherapy. This approval marks the ninth indication for Anlotinib in China and represents the world’s first official approval of an Anlotinib-chemotherapy combination for first-line treatment of advanced or metastatic STS. Previously recommended as a second-line monotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines, Anlotinib was the only Grade I targeted therapy for STS. This new indication represents a significant advancement for patients who have not previously received systemic treatment, expanding access to more effective and targeted first-line the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom